home
Author : adminDate : 2022-04-11 09:27

AACR reveals a 'Real-World Data' of Rivoceranib's Efficacy and safety in HCC

A Real-world Data (RWD) of the efficacy and safety of Rivoceranib (apatinib) in Hepatocellular Carcinoma (HCC) was presented in the poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held in New Orleans, Louisiana, from April 8-13.

 

With the support of Jiangsu Hengrui Medicine (Hengrui), a total of 233 patients who received mono or combined therapy of Rivoceranib with other treatments including TACE and chemotherapy were enrolled in the study across China, including Shandong First Medical University.

As a result, 8 patients achieved complete response (CR), illustrating an Overall Response Rate (ORR) of 30.90% and a Disease Control Rate (DCR) of 82.40%. Median PFS (mPFS) and Overall Survival (mOS) were 6.93 months and 11.36 months respectively and the high efficacy and safety of Rivoceranib has once again been demonstrated.

 

Rivoceranib was approved as an HCC secondary treatment in December of 2020 following a late-stage gastric cancer (GC) treatment in China and is currently on sale. As a result of phase 3 clinical trials of HCC, it was confirmed that the survival rate of 400 patients was significantly improved, and the results were listed in the medical journal ‘The Lancet Gastroenterology & Hepatology’.

 

HLB is currently conducting phase 3 global clinical trials in combination with Hengrui's Camrelizumab (anti-PD-1 monoclonal antibody) to develop Rivoceranib as an HCC primary treatment. Both Rivoceranib and Camrelizumab were individually licensed for sale in China,  so synergy effect between the two drugs is highly expected.

 

Meanwhile, HLB has announced plans to file for NDA for two cases within a year. As HLB is the only Korean company that has entered the NDA stage with a global anticancer drug substance for two to three indications, it draws keen attention both at home and abroad.